Trial Profile
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 01 Dec 2023 Results assessing effect of upadacitinib withdrawal on skin clearance and itch improvement in adult patients with moderate-to-severe AD and evaluate the kinetics of recovery on rescue treatment published in the Journal of the European Academy of Dermatology and Venereology
- 25 Apr 2021 Results (n=2707) assessing short term safety of phase 2b study M16-048 (NCT02925117) and Phase 3 Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318) of upadacitinib in patients with moderate-to-severe atopic dermatitis, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
- 06 Nov 2020 Results published in the Journal of Clinical Pharmacology